RPG Life SciencesNSE:RPGLIFE -0.54%92 EBITDA Margin % is 26.19% as of Mar. 2026, which is 35% above its 10-year median of 19.46. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,359.83 (Fairly Valued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, RPG Life Sciences ranks better than 78.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. RPG Life Sciences's EBITDA for the
three
months ended in Mar. 2026 was ₹463 Mil. RPG Life Sciences's Revenue for the
three
months ended in Mar. 2026 was ₹1,769 Mil. Therefore, RPG Life Sciences's EBITDA margin for the quarter that ended in Mar. 2026 was 26.19%.
RPG Life Sciences (NSE:RPGLIFE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
RPG Life Sciences EBITDA Margin % Related Terms
RPG Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for RPG Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a EBITDA Margin % of 26.19% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RPG Life Sciences and its competitors. This is 35% above median its historical median of 19.46. Over the past decade, RPG Life Sciences' EBITDA Margin % has ranged from 10.02 to 39.01. According to the industry distribution chart, RPG Life Sciences ranks #208 out of 955 companies in the Drug Manufacturers industry, placing it in the top 21.8%.
Is RPG Life Sciences' EBITDA Margin % too high?
RPG Life Sciences' current EBITDA Margin % of 26.19% is 35% above median its 10-year median of 19.46. Over the past 10 years, this metric has ranged from a low of 10.02 to a high of 39.01. The Drug Manufacturers industry median EBITDA Margin % is 12.44. RPG Life Sciences' value of 26.19% is 110.5% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #208 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #208 out of 955 companies for EBITDA Margin %. This places RPG Life Sciences in the top 22% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. RPG Life Sciences' value of 26.19% is 110.5% above this benchmark. Historically, RPG Life Sciences' own EBITDA Margin % has ranged from 10.02 to 39.01 over the past decade. While the company's 10-year median is 19.46 vs. the industry median of 12.44, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current EBITDA Margin % of 26.19% is 110.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current EBITDA Margin % is 26.19%, which is 35% above median its own 10-year median of 19.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,359.83, compared to a current price of ₹2,276.40 — trading 3.5% below its estimated fair value. The current EBITDA Margin % is 26.19%, which is 35% above median its 10-year median of 19.46 and 110.5% above the Drug Manufacturers industry median of 12.44. RPG Life Sciences' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current EBITDA Margin % is 26.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be undervalued.
The current stock price of ₹2,276.40 is trading 3.5% below its estimated GF Value™ of ₹2,359.83.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
EBITDA Margin %: 26.19% (35% above median its 10-year median of 19.46)
GF Value™: ₹2,359.83 vs. price of ₹2,276.40 (3.5% below fair value)
Industry Position: 110.5% above the Drug Manufacturers median (#208 of 955)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score
Get the complete analysis for NSE:RPGLIFE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
